Akin Akinc

Alnylam Pharmaceuticals (United States) — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

44h-index24.1kcitations77works5.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

RNA Interference and Gene Delivery(50), Advanced biosensing and bioanalysis techniques(44), MicroRNA in disease regulation(27), Hemophilia Treatment and Research(10), Cancer-related gene regulation(8)

Publications77 total

High resistance barrier and prophylactic protection in preclinical models of SARS-CoV-2 with two siRNA combination
Nucleic Acids Research·2024· 5 citedOpen Access
Robust and durable prophylactic protection conferred by RNA interference in preclinical models of SARS-CoV-2
2022Open Access
Knockdown of liver-derived factor XII by GalNAc-siRNA ALN-F12 prevents thrombosis in mice without impacting hemostatic function
Thrombosis Research·2020· 21 citedOpen Access
The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs
Nature Nanotechnology·2019· 1.5k citedOpen Access
Safety evaluation of 2′-deoxy-2′-fluoro nucleotides in GalNAc-siRNA conjugates
Nucleic Acids Research·2019· 77 citedOpen Access
An investigational RNAi therapeutic targeting Factor XII (ALN-F12) for the treatment of hereditary angioedema
RNA·2018· 42 citedOpen Access
Reversal of siRNA-mediated gene silencing in vivo
Nature Biotechnology·2018· 92 cited
In silico Modeling of the Impact of Antithrombin Lowering on Thrombin Generation in Rare Bleeding Disorders
Blood·2017· 6 cited
Impact of enhanced metabolic stability on pharmacokinetics and pharmacodynamics of GalNAc–siRNA conjugates
Nucleic Acids Research·2017· 258 citedOpen Access
Targeting of Antithrombin in Hemophilia A or B with RNAi Therapy
New England Journal of Medicine·2017· 346 citedOpen Access
Fitusiran, an Investigational RNAi Therapeutic Targeting Antithrombin for the Treatment of Hemophilia: Updated Results from a Phase 1 and Phase 1/2 Extension Study in Patients with Inhibitors
Blood·2016· 18 cited
Fitusiran, an Investigational RNAi Therapeutic Targeting Antithrombin for the Treatment of Hemophilia: Updated Results from a Phase 1 and Phase 1/2 Extension Study in Patients without Inhibitors
Blood·2016· 24 cited
Inside Cover: 5′‐(<i>E</i>)‐Vinylphosphonate: A Stable Phosphate Mimic Can Improve the RNAi Activity of siRNA–GalNAc Conjugates (ChemBioChem 11/2016)
ChemBioChem·2016Open Access
5′‐(<i>E</i>)‐Vinylphosphonate: A Stable Phosphate Mimic Can Improve the RNAi Activity of siRNA–GalNAc Conjugates
ChemBioChem·2016· 132 cited
An Investigational RNAi Therapeutic Targeting Factor XII (ALN-F12) for the Treatment of Hereditary Angioedema
Journal of Allergy and Clinical Immunology·2016· 5 citedOpen Access
A Subcutaneously Administered Investigational RNAi Therapeutic (ALN-AT3) Targeting Antithrombin for Treatment of Hemophilia: Interim Weekly and Monthly Dosing Results in Patients with Hemophilia A or B
Blood·2015· 17 cited
Antithrombin Reduction Corrected Thrombin Generation in Samples from Hemophilia A and B Patients with Inhibitors
Blood·2015· 5 cited
RNAi-nanoparticulate manipulation of gene expression as a new functional genomics tool in the liver
Journal of Hepatology·2015· 10 citedOpen Access
Identification of siRNA delivery enhancers by a chemical library screen
Nucleic Acids Research·2015· 69 citedOpen Access
An RNAi therapeutic targeting antithrombin to rebalance the coagulation system and promote hemostasis in hemophilia
Nature Medicine·2015· 290 cited
page 1 of 4Next →

Frequent Co-authors

Muthiah Manoharan(25), Martin A. Maier(20), Kallanthottathil G. Rajeev(19), Victor Koteliansky(15), June Qin(15), Kevin Fitzgerald(14), Róbert Langer(14), Daniel G. Anderson(13), Klaus Charissé(12), Muthusamy Jayaraman(11), Scott Barros(9), Pieter R. Cullis(8), Michael J. Hope(8), William Querbes(8), Matthias John(7), Timothy Racie(7), Ying K. Tam(7), Antonin de Fougerolles(7), Jürgen Soutschek(6), Philipp Hadwiger(6)